Showing papers by "James F. Fries published in 1985"
TL;DR: The data indicate that there is not an important increase in deaths due to malignancy in rheumatoid arthritis, and that at least two treatments, gold and prednisone, are not associated with higher risk of malignancies.
54 citations
TL;DR: Differences found in specific toxicity, both clinical and laboratory, between different drugs and with drug combinations are important, and these differences had not been discoverable from pre-marketing studies.
Abstract: ARAMIS, the national arthritis data resource, tracks 22,000 patients from 17 centers by prospective protocol. recording all routine clinical data and with regular assessment of patient status including mortality, disability, discom fort, drug side effects, and economic impact. In the ARAMIS post-marketing surveillance program, these data are used to answer questions of (a) comparative toxicity between drugs, (b) long-term drug effects, (c) effects of drug combinations upon toxicity, (d) effects of comorbidity, (e) generalizability of pre-marketing estimates, and u) clinical characteristics of those with side reactions. Differences found in specific toxicity, both clinical and laboratory, between different drugs and with drug combinations are important, and these differences had not been discoverable from pre-marketing studies.
18 citations
TL;DR: Those studies that are designed best fail to associate rheumatoid arthritis with malignancy, although certain specific malignancies do appear associated with alkylating agent therapy for rhearatoid arthritis.
10 citations